SMTI (57) INGN (29) AVR (36) AGPU (37) ⌘ Pro Terminal →

JIN MEDICAL INTERNATIONAL LTD. (Class A) (ZJYL) — RQD Stock Rating Cockpit

$1.86 -2.10% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $1.85

JIN MEDICAL INTERNATIONAL LTD. (Class A) (ZJYL) carries a Roarable Rating of D (Sell) with 47/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

📊 Historical Track Record Warning: Scores below 50 (47/100 · D) historically underperformed SPY in 71% of rolling 90-day windows →

ROARABLE D • SELL / AVOID Cap $294.2M

📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card

INTERACTIVE SCENARIO DECK:

🛡️ Portfolio Crash X-Ray

EXT / AFTER-HRS: $1.85 (-0.57%)🧬 Dilution Drag (+1.64% YoY Shares)⚙️ Cash Engine: 9/20 (D) • 0% FCF Margin

Verify 90D Bucket Audit →

📊 Historical Track Record Warning: Scores below 50 (47/100 · D) historically underperformed SPY in 71% of rolling 90-day windows (-5.9% avg 90D alpha vs SPY • 29.0% hit rate).

Audit Bucket Track Record →

RQD QUANT TACHOMETERSELL / AVOID • D

2-of-3 JEV AI Jury Bearish Warning

Cash

SEC

Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw D- · Rk D+

Each axis scored 0–20

12M PRICE TARGET CONE-4.8% Base Target

WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for ZJYL)Realized 20D OHLCV Swing Band: ±12.5%

Deterministic 5-Pillar Attribution (47/100 Composite)

🔍 WHY ZJYL SCORES 47/100 (D) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag

▲ #1 Bullish Driver: SEC 10-K Forensic Risk+13/20 pts (28% of score)

Altman Z-Score 3.80 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 4/9

▲ #2 Bullish Driver: Macro Regime Fit+10/20 pts (21% of score)

FRED Regime × Technicals: 5% of 52W Range • RSI-14 at 61 (BULLISH MOMENTUM)

▼ #1 Drag / Risk Factor: Insider Conviction & Share Dilution6/20 pts (-14 pt drag)

Dilution Drag (+1.64% YoY Shares) & executive Form 4 sales trim 14 pts from alignment

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current

Q1 (-3Q)

Grade C$2.06+1% Next Q

Q2 (-2Q)

Grade C-$2.08-1.4% Next Q

Q3 (-1Q)

Grade C-$2.05-9.3% Next Q

Current

Grade D$1.86-5.9% Hist 90D α

Trajectory: C (55) → D (47)Full Audit →

⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER

⚔️ Adversarial Opposing Case: What Could Spark a ZJYL Turnaround Squeeze

Gideon Ashmere Forensic Desk →

While ZJYL currently carries a cautious 47/100 (D) rating due to Insider Conviction & Share Dilution (6/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.

🚀 Contrarian Squeeze Trigger #1

Established market leader in Health Care with deep daily trading liquidity.

🚀 Contrarian Squeeze Trigger #2

Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($2.13) and Max Pain ($1.95) forces dealer call-delta covering toward $8.90.

🚀 Contrarian Squeeze Trigger #3

Forensic Repair Trigger: Halting share dilution (Dilution Drag (+1.64% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.

🎲 LIVE PREDICTION MARKET ODDS TIED TO $ZJYL• $2.4M Crowd Pool • Kalshi / Polymarket Composite

Contract: “ZJYL Beats Next Quarter EPS Consensus (Dec 29, 2026) & Holds Above 200D SMA”

YES 47%NO 53%Trade / Inspect Odds →

RSI-14 MOMENTUMBULLISH MOMENTUM

6130 Oversold · 70 Hot

ALTMAN-Z SHIELDFORTRESS SAFE (>3.0)

3.80>3.0 Fortress Safe

PIOTROSKI F-SCOREWEAK QUALITY (1–4)

4 / 99-Pt Accounting

52-WEEK LASER RANGE5% OF RANGE

L: $2$1.86H: $8

1. Money & Cash Health● WEAK

Are profits real cash in the bank?

Weak cash conversion or heavy valuation strain compared to actual cash earned.

Factor Grade: DRQD 9 / 20

2. Big Money & Insiders● TRIMMING

Are whales & executives buying or selling?

Insiders and big institutional desks have been trimming shares rather than stepping up to buy.

Factor Grade: D-RQD 15 / 40

3. Hidden Risks & Market Weather● WATCH

SEC fine-print scan & interest-rate fit

No major SEC filing blowups, though current interest rates and Fed liquidity call for normal position sizing.

Factor Grade: D+RQD 23 / 40

MULTI-MODEL JEV QUANT JURY DELIBERATION

2-of-3 JEV AI Jury Bearish Warning on ZJYL

Cash & Moat Bull AI

ROIC & Free Cash Flow Model

BEARISH (45)

14.0% ROIC with 29.2% gross margin and -1.27% FCF yield.

SEC Forensic Auditor AI

10-K Accruals & Altman-Z Guard

NEUTRAL (65)

Altman-Z 4.20 and Piotroski 4/9 pass balance-sheet audit.

Whale & Macro Hawk AI

Options Skew, 13F & Fed NetLiq

BEARISH (42)

15/40 institutional & smart-money positioning score with 10/20 macro alignment.

Bull Case: Why Buyers Like ZJYL

✓Established market leader in Health Care with deep daily trading liquidity.

Bear Case: What Could Go Wrong

!Company executives have done more routine share selling than personal cash buying lately.
!Sensitive to high interest rates and tighter Federal Reserve market liquidity.

ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring ZJYL)

✓Walkthrough of ZJYL's RQD Radar, SEC cash-conversion gap & downside invalidation levels
✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks

RQD INSIDER CLUB WAITLIST$49/YR PLANNED

Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?

Join Founding VIP Waitlist (No Card Required) →$100K Arena

ZJYL // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -11.85%▼ DESCENDING CHANNEL

2026-10-30O $1.90H $2.83L $1.83C $1.86VOL 3.66M

RES: $2.80SUP: $0.93SMA50: $2.13SMA200: $2.35

PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

ZJYL Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 ZJYL Butterfly Map → + Track ZJYL →

Share Count & Dilution Monitor (#25)

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle (#30)

40.9%/yr Implied 5Y Growth

vs. -12.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger (#33)

No active Ellis Vennor swing setup published on ZJYL today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for ZJYL. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video

🎬 No recent verified company-specific video clip queued for ZJYL today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →

DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (ZJYL)

Health Care Rank #411 of 1016 ⚔️ SMTI vs ZJYL Full Matrix →

1. Head-to-Head Health Care Peer Comparison (ZJYL vs. SMTI, INGN, AVR, AGPU)

Industry: Industrial Specialties (55 Tracked Issuers)

Across 1016 tracked Health Care securities in the Roarable RQD universe, JIN MEDICAL INTERNATIONAL LTD. (Class A) (ZJYL) ranks #411 by composite RQD confidence (47/100, grade D) and #520 by equity capitalization ($294.2M). Within this direct 5-issuer industry benchmark cohort, SMTI leads on earnings valuation at 8.1x trailing P/E, while SMTI leads on capital efficiency and profitability with 16.3% ROIC and 92.7% gross margin. SMTI currently holds the highest overall quantitative score in the immediate peer group at 57/100 (D+) compared with ZJYL at 47/100 (D).

Ticker / Company	Roarable Grade	RQD Score	Trailing P/E	Gross Margin	ROIC	1D Change	Market Cap	Head-to-Head
ZJYL ACTIVE JIN MEDICAL INTERNATIONAL LTD. (Class A)	D	47/100	—	29.2%	—	-2.10%	$294.2M	Benchmark Subject
SMTI Sanara MedTech Inc.	D+	57/100	8.1x	92.7%	16.3%	+0.11%	$302.4M	/smti-vs-zjyl →
INGN Inogen Inc	E	29/100	8.5x	52.2%	-27.0%	+0.14%	$192.7M	/ingn-vs-zjyl →
AVR Anteris Technologies Global Corp.	D-	36/100	—	70.3%	-35.0%	+5.25%	$625.9M	/avr-vs-zjyl →
AGPU Axe Compute Inc.	D-	37/100	—	—	-35.0%	-2.01%	$101.7M	/agpu-vs-zjyl →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-09-30 • CIK 0001837821

In its most recent audited fiscal period (FY2025, filed 2025-09-30), JIN MEDICAL INTERNATIONAL LTD. (Class A) (ZJYL) reported GAAP revenue of $20.7M (-12.0% vs. FY2024 revenue of $23.5M , and +4.4% cumulative change since FY2023) , GAAP net income of $1.2M, operating cash flow of $2.9M, and free cash flow of -$3.7M (-175.6% YoY). On the balance sheet, ZJYL closed FY2025 with $53.4M in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: 4/9).

Fiscal Period	Filing Date	Revenue	Net Income	Operating Cash Flow	Free Cash Flow	Total Assets	Total Debt
FY2025 (FY)	2025-09-30	$20.7M	$1.2M	$2.9M	-$3.7M	$53.4M	—
FY2024 (FY)	2024-09-30	$23.5M	$3.7M	-$1.2M	-$1.4M	—	—
FY2023 (FY)	2023-09-30	$19.8M	$2.9M	$3.1M	$3.1M	—	—

3. ZJYL Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is ZJYL stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-01, JIN MEDICAL INTERNATIONAL LTD. (Class A) (NASDAQ: ZJYL) is rated D (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 47/100 at a spot price of $1.86 (-2.10% 1D, market cap $294.2M). Pillar breakdown: Fundamental Cash Engine 9/20, Institutional 13F & Options Flow 9/20, Executive Insider Alignment 13/20, FRED Macro Regime Fit 10/20, and SEC Balance-Sheet Forensics 6/20. Across 1016 tracked Health Care issuers, ZJYL ranks #411 in composite RQD confidence.

How does ZJYL compare to SMTI and INGN in the Health Care sector?

Within the Health Care sector (Industrial Specialties), ZJYL carries a Roarable D (47/100 RQD), trailing P/E of N/A, gross margin of 29.2%, and ROIC of —. By comparison, SMTI (Sanara MedTech Inc.) holds a D+ grade (57/100 RQD, P/E 8.1x, ROIC 16.3%, cap $302.4M) and INGN (Inogen Inc) posts a E grade (29/100 RQD, P/E 8.5x, ROIC -27.0%, cap $192.7M). Among the 5-stock peer group, SMTI leads on earnings multiple (8.1x) while SMTI leads on capital efficiency (16.3% ROIC).

What are the biggest fundamental strengths and SEC risk factors for ZJYL?

Per ZJYL's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-09-30, CIK 0001837821), JIN MEDICAL INTERNATIONAL LTD. (Class A) generated $20.7M in revenue (-12.0% YoY), $1.2M in net income, and -$3.7M in free cash flow against $53.4M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.

Where is ZJYL trading relative to its 50-day, 200-day, and 52-week technical levels?

ZJYL last traded at $1.86 (-2.10% on volume of 1,620 shares), positioning the stock -12.68% below its 50-day simple moving average ($2.13) and -20.85% below its 200-day simple moving average ($2.35). Across its 52-week range of $1.53 to $8.48, ZJYL sits at the 4.7% percentile with a 14-day RSI of 61.0 (BULLISH MOMENTUM) and an implied next-earnings move of ±12.5% ($1.63 to $2.09).

ZJYL Investor FAQ & Complete 8-Part Research Index

100% OPEN ACCESS • SEC EDGAR × CBOE × FRED

Should I buy, hold, or sell ZJYL stock right now?

JIN MEDICAL INTERNATIONAL LTD. (Class A) (ZJYL) currently earns a Roarable Rating of D (Sell — SELL) with 47/100 RQD Confidence. Stretched risk/reward at current multiples (29% profit margin) under elevated 10-year interest-rate pressure.

What is ZJYL's 12-month price target and RQD AI Jury consensus?

ZJYL's 12-month base price target is $1.77 (range $1.38 to $8.9), backed by transparent SEC XBRL cash-flow, Form 4 insider, and CBOE options flow analysis.

Direct Sub-Reports: ZJYL RQD Cockpit ZJYL 12M Forecast ZJYL Earnings & Move ZJYL Dividends & DRIP ZJYL Insiders & 13F ZJYL Whale Options ZJYL Profit Sankey ZJYL News & Why